Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 9.52 is in line with its 5-year average of 9.19, near the low end of its 5-year range (2.40–33.20).
As of the fiscal period ended Tuesday, June 30, 2026. 22.48% above its 12-month average of 7.78.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 9.52.
QUICK RATIO (ACID-TEST)
9.52
QUICK RATIO (ACID-TEST) AVG TTM
7.78
QUICK RATIO (ACID-TEST) AVG 3Y
6.80
QUICK RATIO (ACID-TEST) AVG 5Y
9.19
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+22.48%
CURRENT VS 3Y AVG
+40.11%
CURRENT VS 5Y AVG
+3.59%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.28
median of 794 covered companies
CURRENT VS SECTOR MEDIAN
+190.38%
vs the sector median at left
Monte Rosa Therapeutics, Inc.
Market Cap
$839.73M
Quick Ratio (Acid-Test)
9.52
TTM Avg
7.78
3Y Avg
6.80
5Y Avg
9.19
Market Cap
$840.18M
Quick Ratio (Acid-Test)
25.06
TTM Avg
12.67
3Y Avg
12.67
5Y Avg
12.67
Market Cap
$832.41M
Quick Ratio (Acid-Test)
4.03
TTM Avg
6.29
3Y Avg
5.71
5Y Avg
7.79
Market Cap
$833.62M
Quick Ratio (Acid-Test)
7.96
TTM Avg
6.81
3Y Avg
6.62
5Y Avg
6.62
Market Cap
$858.87M
Quick Ratio (Acid-Test)
0.76
TTM Avg
0.79
3Y Avg
0.88
5Y Avg
1.73
Market Cap
$863.01M
Quick Ratio (Acid-Test)
3.05
TTM Avg
34.00
3Y Avg
26.34
5Y Avg
26.34
Market Cap
$861.70M
Quick Ratio (Acid-Test)
7.55
TTM Avg
6.94
3Y Avg
6.93
5Y Avg
8.87
Market Cap
$865.07M
Quick Ratio (Acid-Test)
1.79
TTM Avg
2.17
3Y Avg
1.93
5Y Avg
2.04
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | $839.73M | 9.52 | 7.78 | 6.80 | 9.19 |
| Alumis Inc. (ALMS)vs › | $835.64M | 6.74 | 5.17 | 5.15 | 5.15 |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $840.18M | 25.06 | 12.67 | 12.67 | 12.67 |
| Pacific Biosciences of California, Inc. (PACB)vs › | $832.41M | 4.03 | 6.29 | 5.71 | 7.79 |
| Beta Bionics, Inc. (BBNX)vs › | $833.62M | 7.96 | 6.81 | 6.62 | 6.62 |
| QuidelOrtho Corporation (QDEL)vs › | $858.87M | 0.76 | 0.79 | 0.88 | 1.73 |
| SL Science Holding Ltd (SLBT)vs › | $863.01M | 3.05 | 34.00 | 26.34 | 26.34 |
| SI-BONE, Inc. (SIBN)vs › | $861.70M | 7.55 | 6.94 | 6.93 | 8.87 |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $865.07M | 1.79 | 2.17 | 1.93 | 2.04 |
| Jade Biosciences, Inc. (JBIO)vs › | $810.71M | 14.93 | 20.63 | 16.30 | 22.70 |
Quick Ratio
9.52
Excludes inventory
Current Ratio
9.52
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 9.52 |
| 2026-03-31 | 9.54 |
| 2025-12-31 | 6.12 |
| 2025-09-30 | 6.54 |
| 2025-06-30 | 7.16 |
| 2025-03-31 | 5.61 |
| 2024-12-31 | 2.40 |
| 2024-09-30 | 6.03 |
| 2024-06-30 | 6.56 |
| 2024-03-31 | 4.82 |
| 2023-12-31 | 5.07 |
| 2023-09-30 | 8.09 |
| 2023-06-30 | 10.90 |
| 2023-03-31 | 11.73 |
| 2022-12-31 | 10.79 |
| 2022-09-30 | 13.55 |
| 2022-06-30 | 20.11 |
| 2022-03-31 | 25.65 |
| 2021-12-31 | 20.96 |
| 2021-09-30 | 29.08 |
| 2021-06-30 | 33.20 |
| 2021-03-31 | 18.89 |
| 2020-12-31 | 1.49 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
